专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US09642798B2 Monovalent metal cation dry powders for inhalation 有权
公开(公告)号：US09642798B2
公开(公告)日：2017-05-09
申请号：US13876312
申请日：2011-09-29
申请人： Michael M. Lipp , Jean C. Sung
发明人： Michael M. Lipp , Jean C. Sung
IPC分类号： A61K9/00 , A61K31/137 , A61K31/407 , A61K31/4745 , A61K31/5383 , A61K31/56 , A61K38/00 , A61K38/28 , A61K39/00
CPC分类号： A61K9/0073 , A61K9/0075 , A61K31/137 , A61K31/407 , A61K31/439 , A61K31/4745 , A61K31/496 , A61K31/5383 , A61K31/56 , A61K31/58 , A61K31/7036 , A61K38/00 , A61K38/28 , A61K39/00 , A61K39/395 , A61K2300/00
摘要： The present invention is directed toward respirable dry powders and particles for systemic delivery of pharmaceutically active agents or delivery to the respiratory tract. The dry powders contain one or more monovalent metal cations (such as Na+), are small and dispersible.

2. 发明申请

US20150079173A1 FORMULATIONS DECREASING PARTICLE EXHALATION 审中-公开
标题翻译：制剂减少颗粒物排放
公开(公告)号：US20150079173A1
公开(公告)日：2015-03-19
申请号：US14058852
申请日：2013-10-21
申请人： PULMATRIX, INC.
发明人： David A. EDWARDS , Jonathan Chun-Wah MAN , Jeffrey P. KATSTRA , Robert W. CLARKE
IPC分类号： A61K47/02 , A61K9/00
CPC分类号： A61K47/02 , A61K9/0078 , A61K9/14 , A61K9/141 , A61K9/16 , A61M15/00
摘要： Formulations have been developed for pulmonary delivery to treat or reduce the infectivity of diseases such as viral infections, especially tuberculosis, SARS, influenza and respiratory synticial virus in humans and hoof and mouth disease in animals, or to reduce the symptoms of allergy or other pulmonary disease. Formulations for pulmonary administration include a material that significantly alters physical properties such as surface tension and surface elasticity of lung mucus lining fluid, which may be isotonic saline and, optionally, a carrier. The formulation may be administered as a liquid solution, suspension, aerosol, or powder where the particles consist basically of an osmotically active solute. Drugs, especially antivirals or antibiotics, may optionally be included with the formulation. These may be administered with or incorporated into the formulation.
摘要翻译：已经开发了用于肺部输送以治疗或降低人类感染病毒感染，特别是结核病，SARS，流感和呼吸道合成病毒以及动物蹄和口蹄疫等疾病或减轻过敏或其他肺部疾病症状的传染性的制剂疾病。用于肺部给药的制剂包括显着改变诸如等渗盐水和任选的载体的肺粘液衬里液体的表面张力和表面弹性的物理性质的材料。制剂可以作为液体溶液，悬浮液，气雾剂或粉末施用，其中颗粒基本上由渗透活性的溶质组成。药物，特别是抗病毒剂或抗生素，可以任选地包括在制剂中。这些可以与制剂一起施用或掺入制剂中。

3. 发明申请

US20120107414A1 PHARMACEUTICAL FORMULATIONS AND METHODS FOR TREATING RESPIRATORY TRACT INFECTIONS 审中-公开
标题翻译：药物制剂和治疗呼吸道感染的方法
公开(公告)号：US20120107414A1
公开(公告)日：2012-05-03
申请号：US13259651
申请日：2010-03-26
申请人： Michael M. Lipp , Robert W. Clarke , David L. Hava , Richard Batycky , John Hanrahan
发明人： Michael M. Lipp , Robert W. Clarke , David L. Hava , Richard Batycky , John Hanrahan
IPC分类号： A61K33/42 , A61K33/10 , A61K33/06 , A61K33/00 , A61K33/04 , A61K33/22 , A61K31/19 , A61K31/734 , A61K31/20 , A61K31/191 , A61K31/194 , A61K31/375 , A61K31/192 , A61P31/00 , A61K33/14
CPC分类号： A61K31/19 , A61K9/0078 , A61K31/194 , A61K31/20 , A61K31/734 , A61K33/00 , A61K33/04 , A61K33/06 , A61K33/10 , A61K33/14 , A61K33/42 , A61K45/06 , Y02A50/473 , Y02A50/478 , A61K2300/00
摘要： The present invention relates to pharmaceutical formulations for treating a respiratory tract infection or a pulmonary disease in an individual, comprising a calcium salt and a sodium salt, wherein the ratio of Ca+2 to Na+ is from about 4:1 (mole:mole) to about 16:1 (mole:mole). The invention also relates to methods of treating (including prophylactically treating) and reducing the spread of a respiratory tract infection, methods of treating (including prophylactically treating) a pulmonary disease or an acute exacerbation of a pulmonary disease, and methods of reducing the spread of an acute exacerbation of a pulmonary disease, comprising administering a pharmaceutical formulation that comprises a calcium salt and a sodium salt.
摘要翻译：本发明涉及用于治疗个体中的呼吸道感染或肺部疾病的药物制剂，其包含钙盐和钠盐，其中Ca + 2与Na +的比例为约4:1（摩尔：摩尔）至约16：1（摩尔：摩尔）。本发明还涉及治疗（包括预防性治疗）和减少呼吸道感染扩散的方法，治疗（包括预防性治疗）肺部疾病或肺部疾病急性加重的方法，以及减少是肺疾病的急性恶化，包括施用包含钙盐和钠盐的药物制剂。

4. 发明申请

US20120070417A1 ANTI-INFLUENZA FORMULATIONS AND METHODS 审中-公开
标题翻译：抗流感制剂和方法
公开(公告)号：US20120070417A1
公开(公告)日：2012-03-22
申请号：US13259659
申请日：2010-03-26
申请人： Richard Batycky , David L. Hava , Robert W. Clarke , Michal M. Lipp
发明人： Richard Batycky , David L. Hava , Robert W. Clarke , Michal M. Lipp
IPC分类号： A61K33/14 , A61K38/21 , A61K31/19 , A61K31/715 , A61P31/16 , A61K31/7105 , A61K31/351 , A61K31/195 , A61K31/245 , A61K38/47 , A61K31/713
CPC分类号： A61K47/183 , A61K9/0075 , A61K9/0078 , A61K9/1617 , A61K9/1694 , A61K31/125 , A61K31/155 , A61K31/196 , A61K31/454 , A61K33/06 , A61K33/14 , A61K45/06 , A61K2300/00
摘要： The invention relates to pharmaceutical compositions that contain a calcium salt as an active ingredient and also comprise another anti-influenza agent, and to methods for treating or preventing influenza virus infection.
摘要翻译：本发明涉及含有钙盐作为活性成分并且还包含另一种抗流感药物的药物组合物，以及用于治疗或预防流感病毒感染的方法。

5. 发明授权

US09233158B2 Dry powder formulations and methods for treating pulmonary diseases 有权
公开(公告)号：US09233158B2
公开(公告)日：2016-01-12
申请号：US14717243
申请日：2015-05-20
申请人： Pulmatrix, Inc.
发明人： Michael M. Lipp , Jean C. Sung , Robert W. Clarke , David L. Hava
IPC分类号： A61K47/02 , A61K9/00 , A61K31/198 , A61K33/06 , A61K33/14 , A61M15/00 , B22F3/11 , B22F5/10 , C22C21/00 , A61K31/137 , A61K47/12 , A61K47/18
CPC分类号： A61K47/02 , A61K9/0073 , A61K9/0075 , A61K31/137 , A61K31/198 , A61K33/06 , A61K33/14 , A61K47/12 , A61K47/183 , A61K2300/00 , A61M15/00 , B22F3/1125 , B22F5/10 , C22C21/00
摘要： The present invention is directed toward respirable dry particles for delivery of divalent metal cation salts and/or monovalent cation salts to the respiratory tract and methods for treating a subject having a respiratory disease and/or infection.

6. 发明申请

US20130243828A1 CATIONIC DRY POWDERS 有权
标题翻译：阳离子干粉
公开(公告)号：US20130243828A1
公开(公告)日：2013-09-19
申请号：US13876315
申请日：2011-09-29
申请人： Michael M. Lipp , Jean C. Sung
发明人： Michael M. Lipp , Jean C. Sung
IPC分类号： A61K9/00
CPC分类号： A61K9/0075 , A61K9/1611 , A61K31/198 , A61K31/5383 , A61K33/06 , A61K33/14 , A61K47/02 , A61K2300/00
摘要： The invention relates to respirable dry particles that contain one or more divalent metal cations, such as calcium, in an amount of less than 3% by weight, and to dry powders that contain the respirable particles. The dry particles can further contain an active agent, or can be used as carrier particles to deliver an active agent.
摘要翻译：本发明涉及含有少于3重量％的一种或多种二价金属阳离子如钙的可呼吸干燥颗粒，以及含有可吸入颗粒的干燥粉末。干颗粒可以进一步含有活性剂，或可用作载体颗粒以递送活性剂。

7. 发明申请

US20050207983A1 Formulations decreasing particle exhalation 审中-公开
标题翻译：减少颗粒呼气的配方
公开(公告)号：US20050207983A1
公开(公告)日：2005-09-22
申请号：US10990996
申请日：2004-11-17
申请人： David Edwards , Jonathan Man , Jeffrey Katstra , Robert Clarke
发明人： David Edwards , Jonathan Man , Jeffrey Katstra , Robert Clarke
IPC分类号： A61K9/00 , A61K47/02 , A61L9/04 , A61K31/70 , A61K31/715 , A61K38/17 , A61K48/00
CPC分类号： A61K47/02 , A61K9/0078 , A61K9/14 , A61K9/141 , A61K9/16 , A61M15/00
摘要： Formulations have been developed for pulmonary delivery to treat or reduce the infectivity of diseases such as viral infections, especially tuberculosis, SARS, influenza and respiratory synticial virus in humans and hoof and mouth disease in animals, or to reduce the symptoms of allergy or other pulmonary disease. Formulations for pulmonary administration include a material that significantly alters physical properties such as surface tension and surface elasticity of lung mucus lining fluid, which may be isotonic saline and, optionally, a carrier. The formulation may be administered as a liquid solution, suspension, aerosol, or powder where the particles consist basically of an osmotically active solute. Drugs, especially antivirals or antibiotics, may optionally be included with the formulation. These may be administered with or incorporated into the formulation.
摘要翻译：已经开发了用于肺部输送以治疗或降低人类感染病毒感染，特别是结核病，SARS，流感和呼吸道合成病毒以及动物蹄和口蹄疫等疾病或减轻过敏或其他肺部疾病症状的传染性的制剂疾病。用于肺部给药的制剂包括显着改变诸如等渗盐水和任选的载体的肺粘液衬里液体的表面张力和表面弹性的物理性质的材料。制剂可以作为液体溶液，悬浮液，气雾剂或粉末施用，其中颗粒基本上由渗透活性的溶质组成。药物，特别是抗病毒剂或抗生素，可以任选地包括在制剂中。这些可以与制剂一起施用或掺入制剂中。

8. 发明授权

US09433576B2 Cationic dry powders 有权
标题翻译：阳离子干粉
公开(公告)号：US09433576B2
公开(公告)日：2016-09-06
申请号：US13876315
申请日：2011-09-29
申请人： Michael M. Lipp , Jean C. Sung
发明人： Michael M. Lipp , Jean C. Sung
IPC分类号： A61K9/00 , A61K9/16 , A61K31/198 , A61K33/14 , A61K33/06
CPC分类号： A61K9/0075 , A61K9/1611 , A61K31/198 , A61K31/5383 , A61K33/06 , A61K33/14 , A61K47/02 , A61K2300/00
摘要： The invention relates to respirable dry particles that contain one or more divalent metal cations, such as calcium, in an amount of less than 3% by weight, and to dry powders that contain the respirable particles. The dry particles can further contain an active agent, or can be used as carrier particles to deliver an active agent.
摘要翻译：本发明涉及含有少于3重量％的一种或多种二价金属阳离子如钙的可呼吸干燥颗粒，以及含有可吸入颗粒的干燥粉末。干颗粒可以进一步含有活性剂，或可用作载体颗粒以递送活性剂。

9. 发明申请

US20150004233A1 RESPIRABLY DRY POWDER COMPRISING CALCIUM LACTATE, SODIUM CHLORIDE AND LEUCINE 有权
标题翻译：包含氯酸钙，氯化钠和光亮剂的可呼吸干粉
公开(公告)号：US20150004233A1
公开(公告)日：2015-01-01
申请号：US14284880
申请日：2014-05-22
申请人： PULMATRIX, INC.
发明人： Michael M. LIPP , Jean C. SUNG
IPC分类号： A61K33/14 , A61K31/198 , A61K9/14 , A61K9/00 , A61M15/00 , A61K31/56 , A61K31/138 , A61K31/439 , A61K31/5383 , A61K31/137 , A61K33/06 , A61K45/06
CPC分类号： A61K9/14 , A61K9/0075 , A61K9/1611 , A61K9/1617 , A61K31/19 , A61K31/198 , A61K31/56 , A61K33/06 , A61K33/14 , A61K45/06 , Y02A50/473 , A61K2300/00
摘要： The present invention relates to respirable dry powders that contain respirable dry particles that comprise about 20%-37.5% (w/w) leucine, about 58.6-about 75% (w/w) calcium lactate, and about 3.9-about 5% (w/w) sodium chloride, and methods for treating a subject using the respirable dry powders.
摘要翻译：本发明涉及包含可吸入干颗粒的可呼吸干粉，其包含约20％-37.5％（w / w）亮氨酸，约58.6-约75％（w / w）乳酸钙和约3.9-约5％ w / w）氯化钠，以及使用可呼吸干燥粉末治疗受试者的方法。

10. 发明申请

US20130281361A1 METHODS OF TREATING AND PREVENTING RHINOVIRUS INFECTION 审中-公开
标题翻译：治疗和预防恶病毒感染的方法
公开(公告)号：US20130281361A1
公开(公告)日：2013-10-24
申请号：US13883912
申请日：2011-11-04
申请人： David L. Hava , Robert W. Clarke
发明人： David L. Hava , Robert W. Clarke
IPC分类号： A61K38/17
CPC分类号： A61K38/1729 , A61K38/17
摘要： The present invention relates to methods of treating or preventing non-enveloped viral infection and/or disease caused by non-enveloped virus infection, particularly a viral infection caused by rhino virus. The methods comprise administering to an individual in need thereof an effective amount of a defensin peptide. The defensin peptide may be selected from α-, β-, or θ-defensins.
摘要翻译：本发明涉及治疗或预防由非包膜病毒感染引起的非包膜病毒感染和/或疾病的方法，特别是由犀病毒引起的病毒感染。所述方法包括向有需要的个体施用有效量的防御素肽。防御素肽可以选自α-，β-或θ-防御素。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式